Abstract BRCA1 and BRCA2 genes are essential in preserving the integrity of genome, and it is not unambiguously clear whether the heterozygosity status may affect BRCA1 or BRCA2 functions. This may have implications for the clinical management of BRCA1 and BRCA2 mutation carriers both in breast cancer (BC) screening modality and in cancer treatment based on DNA-damaging or DNA-repairinhibiting drugs. We investigated whether lymphocytes carrying BRCA1 or BRCA2 mutations displayed an increased sensitivity to radiation or mitomycin C (MMC) in vitro treatments. Peripheral blood from 21 BRCA1 mutation carriers (12 with BC and 9 healthy), 24 BRCA2 carriers (13 with BC and 11 healthy), 15 familial BC patients without detected mutation in BRCA1 or BRCA2 and 16 controls without familial history of cancer (5 with BC and 11 healthy) were irradiated or treated with MMC. Chromosomal damage was measured using the cytokinesis-block micronucleus assay. We evaluated micronuclei (MN) and nucleoplasmic bridges (NPBs). The BRCA2 mutation carriers and familial BC patients without detected mutation in BRCA1 or BRCA2 showed less basal NPB than BRCA1 carriers and controls. The BRCA1
Introduction
Heterozygous germline mutations in BRCA1 or BRCA2 tumour suppressor genes (BRCA1/2) confer susceptibility to breast (BC) and ovarian cancers (OC) with high penetrance, and account for approximately 20% of BC cases associated with family history [reviewed in Ref. 1] .
BRCA1/2 genes are important in the maintenance of genome stability. The main role of BRCA2 appears to involve regulation of the RAD51 function in DNA repair by homologous recombination. BRCA1 is an E3 ubiquitin ligase that has a broader role upstream of BRCA2, participating in DNA repair, transcriptional regulation, cell cycle progression and meiotic sex chromosome inactivation [reviewed in Refs. 2, 3] . BRCA1
-/-or BRCA2 -/-cells from chicken DT40 knockout cell lines, knockout mice and tumour-derived human cell lines exhibit spontaneous chromosomal instability and are hypersensitive to DNAdamaging agents such as ionising radiation (IR) and DNA cross-linking agents [2, 3] .
In contrast, whether some functions of the BRCA1/2 proteins are diminished or deregulated while still heterozygous or only after the loss of both functional alleles is not yet well established [4, 5] . The heterozygous status (BRCA1 ?/-or BRCA2 ?/-) might contribute to the impairment of genomic stability and increase the risk of cancer promoting mutations, contributing to the loss of the remaining wild-type BRCA1/2 allele [4] [5] [6] . Since BRCA1 and BRCA2 proteins are involved in DNA repair, BRCA1
?/-or BRCA2 ?/-cells of mutation carriers may also have enhanced sensitivity to DNA-damaging agents, such as IR or mitomycin C (MMC); this phenotype may increase toxicity and the carcinogenic risk of chemotherapy, radiotherapy and mammography screening in BRCA1 or BRCA2 mutation carriers [4, 5] . If the functions of the BRCA1/2 proteins are affected by heterozygosity status, two mechanisms may explain this phenotype: haploinsufficiency or reduction in gene dosage, and/or dominant negative mutations. Several studies have claimed the existence of phenotypes associated with BRCA1/2 haploinsufficiency, whereas others have raised the possibility that BRCA1 or BRCA2 mutated proteins may block the function of the remaining wild-type BRCA1/2 allele [reviewed in Ref. 4] .
Several studies in blood lymphocytes to know whether the heterozygosity for BRCA1/2 mutations confers detectable sensitivity to genotoxic agents have been performed with contradictory results [reviewed in Ref. 7] . Here, we have studied chromosomal sensitivity to IR or MMC treatments of peripheral blood lymphocytes from BRCA1 or BRCA2 germ-line mutation carriers with or without BC, familial BC patients without detected mutation in BRCA1/2, and controls with or without BC and no familial history of cancer. The chromosomal damage was measured by quantification of micronuclei (MN) and nucleoplasmic bridges (NPBs) using the cytokinesis-block micronucleus (CBMN) assay. The in vitro proliferation capacity of the treated lymphocytes was also evaluated by the nuclear division index (NDI).
The MN in dividing cells are the result of fragments or whole acentric chromosomes/chromatids that lag behind in anaphase and are not included in the daughter nuclei in telophase [8] . These fragments can be originated from nonrepaired or misrepaired DNA double-strand breaks (DSBs) [8] . Misrepair of DSBs could also lead to the formation of asymmetrical chromosome rearrangements producing dicentrics or ring chromosomes and acentric fragments. The centromeres of the dicentric chromosomes, dicentric ring chromosomes or concatenated double rings can be pulled to opposite poles of the cells at anaphase resulting in the formation of NPBs between the daughter nuclei [9] . Therefore, the presence of MN or NPB could indirectly reflect the cell DNA repair capacity [8] . In fact, increased frequencies of spontaneous and mutagen induced MN or NPBs have been observed in different cells deficient in DNA repair mechanisms such as non-homologous DNA end-joining [10] or homologous recombination [11, 12] .
The CBMN assay is the preferred method for measuring MN in cultured human cells because scoring is specifically restricted to once-divided binucleated (BN) cells, which are the cells that can show MN [8] . The inhibition of cytokinesis by cytochalasin-B allows to discriminate between cells that did not divide after treatment and cells that did divide, thus preventing the confounding effects caused by differences in cell division kinetics [8] . Because cells are blocked in the BN stage, it is also possible to measure NPBs [9] . In addition to MN in binucleated cells and NPB, the CBMN assay also allows for scoring of other critical events, such as cell division and cell cytotoxicity by scoring of proportion of mono-, bi-and multinucleated cells to calculate the NDI [8] . To date the CBMN assay is one of the best-validated methods for measuring chromosome damage in human lymphocytes [13] .
Materials and methods

Subjects and study design
Heparinized blood samples were collected from 76 women between 2004 and 2007: 60 with a family history of BC and OC and 16 without a family history of cancer. The ethical committee of the hospital approved the study and all women participating signed an informed consent.
Women with a family history of cancer were recruited from those attending the Cancer Genetics Clinic of Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Subjects were referred for genetic assessment because of familial BC/OC, early onset BC or previous identified BRCA1/2 mutation in the family. The mutation analysis of the BRCA1 and BRCA2 genes was performed in women fulfilling one of the following criteria: families with one or more cases of BC (at least 1 case diagnosed before age 50) and 1 or more cases of OC; site-specific female BC families with 2 or more cases (at least 1 diagnosed at 50 years of age); families with at least 1 case of BC or OC in addition to at least 1 male case of BC.
The entire coding sequence of BRCA1 and BRCA2 was analyzed for sequence variants using denaturing high-performance liquid chromatography (DHPLC) and for large deletions and duplications using Multiplex Ligationdependent Probe Amplification (MLPA) (MRC Holland). In those women referred due to a BRCA1/2 mutation previously identified in the family, the analysis was performed by direct sequencing or MLPA.
The mutational status of the 60 individuals with family history was: 21 BRCA1 mutation carriers (12 with BC and 9 healthy), 24 BRCA2 mutation carriers (13 with BC and 11 healthy) and 15 females with familial BC/OC without detected mutation in BRCA1/2 (14 with BC and 1 with OC). The BRCA1/2 mutations are shown in Table 1 .
As controls, blood samples were also collected from 16 women without family history of BC/OC: five with sporadic BC and 11 healthy women. The sporadic BC patients came from those attending the Medical Oncology Department and the healthy subjects were recruited from the laboratory staff of the Genetics Department of the Hospital.
Considering the disease status of the analysed subjects, 31 were healthy and 45 had BC/OC. Most of the BC/OC patients (n = 31) had received different combinations of adjuvant chemotherapy: cyclophosphamide, methotrexate and 5-fluorouracil (CMF) (n = 7); 5-fluorouracil, epirubicin and cyclophosphamide (FEC) (n = 6); adriamycin and cyclophosphamide (n = 3); FEC in a high-dose chemotherapy regimen (with autologous transplantation) (n = 2); FEC, trastuzumab and taxanes (n = 2); CMF, adriamycin, taxol and capecitabine (n = 2). The rest of patients (n = 9) received individually different regimens each: FEC, taxanes and carboplatin; cyclophosphamide, adriamycin and taxol; FAC (5-fluorouracil, adriamycin and cyclophosphamide); FEC and taxanes; FAC and taxanes; FEC and CMF; CMF, MMC and vinblastine; anthracyclines; cyclophosphamide. Four patients required neo-adjuvant chemotherapy (2 patients with CMF, 1 with FEC and 1 with epirubicin and doxorubicin). Three patients required chemotherapy because of BC recurrence (one patient was treated with CMF, one with CMF, MMC and vinblastine, and one with MMC and vinblastine).
Culture and treatment with mutagenic agents Peripheral blood cultures were set up by adding 0.5 ml of whole blood to 4.5 ml of RPMI 1640 medium (PAA Laboratories GmbH, Pasching, Austria) supplemented with 15% heat-inactivated foetal calf serum (PAA Laboratories GmbH), 1% antibiotics (penicillin and streptomycin), 1% L-glutamine (provided by Gibco, Invitrogen Corporation, Paisley, United Kingdom) and 1% phytohaemagglutinin (PHA) to stimulate the division of T-lymphocytes (Gibco). Six cultures were set up for each subject immediately after drawing blood: 2 that will be treated in the G 0 phase with 2 Gy of gamma irradiation (before incubation at 37°C with PHA), 2 that will be treated in the G 1 /S phase with 0.05 lg/ml of MMC (24 h after the beginning of the culture with PHA) and 2 replicates without any treatment.
Irradiation of the two respective cultures was done just after re-suspending the blood with the supplemented RPMI 1640 medium. All irradiations were performed at room temperature with 2 Gy of gamma irradiation from a source of Co-60 (Theratron 780 radiotherapy unit, Theratronics Ltd., Canada) at a high-dose rate (HDR) of 0.6-0.8 Gy/min. To minimize the dose gradient within the tubes, the cultures were irradiated at a large distance (80 cm from the cobalt source). A polymethyl methacrylate (PMMA) scattering slab was placed on the irradiated tubes to minimize the build-up effect and to guarantee uniform irradiation.
Immediately after irradiation the 6 cultures per individual were incubated at 37°C. After 24 h of incubation and stimulation with PHA, MMC (Sigma, St. Louis, Missouri, USA) was added to the 2 corresponding cultures to obtain a final concentration of 0.05 lg/ml and cultures were returned to the incubator.
After 44 h of incubation with PHA at 37°C, cytochalasin-B (Cyt-B, Sigma, St. Louis, Missouri, USA) was added to the 6 cultures to a final concentration of 6 lg/ml to arrest cytokinesis. Seventy-two hours after incubation with PHA at 37°C the cells were centrifuged (800 rpm for 8 min at room temperature), the supernatant was aspirated, and the cells were re-suspended in a hypotonic solution (0.075 M KCl) for 3 min at 4°C. The cells were re-centrifuged, and a 3:1 (v/v) methanol:acetic acid solution gently added. This fixation step was repeated twice and the cells were then resuspended in a small volume of fixative solution and dropped onto clean slides. The air-dried slides were subsequently stained with 1 lg/ml of 4 0 ,6-diamidino-2-phenylindole (DAPI; Sigma, St. Louis, Missouri, USA) and 2 lg/ml of propidium iodide (PI; Sigma) in an antifade solution (Vectashield; Vector Laboratories, Burlingame, CA, USA). The slides were stored at 4°C until assessed by microscopy. All slides were randomized and coded before being scored by the same observer to minimize variability. The slides were scored under the 1009 objective of a Nikon Eclipse E400 fluorescence microscope (Nikon, Tokyo, Japan) equipped with a triple-band-pass filter to visualize the nuclei and MN, in bright blue (DAPI), and the cytoplasm, in red (PI). The presence of MN was confirmed using the filter to view only the DAPI stain.
To determine the presence of both MN and NPBs, a total of 1000 binucleated cells with well-preserved cytoplasm for each subject (500 per replicate) were blind scored on coded slides according to previously described criteria [8] . In addition, a total of 500 lymphocytes (250 cells per replicate) were examined to determine the proportion of cells with different numbers of nuclei (1-4 nuclei) in order to calculate the NDI [8] .
Statistical methods
In the untreated cultures, the outcome variables analyzed were the basal values of MN, NPB and NDI. In the treated cultures, the cytogenetic endpoints evaluated were the number of radiation or MMC-induced MN (calculated by subtracting the basal yields from the yields obtained in the treated samples), the absolute values of NPB after the mutagenic treatments and, the NDI index values in untreated cultures less NDI values in treated cultures.
The analysis included 2 factors: carrier/non-carrier, with 4 levels (BRCA1 carrier, BRCA2 carrier, familial BC without detected mutations in BRCA1/2, and controls without familial history of BC/OC) and, disease with 2 levels (healthy women or cancer patients groups). Potential confounding factors of MN were also considered. Age at time of experiments, smoking habit, and number of cigarettes were recorded for all subjects. Given that the blood samples were not obtained concurrently and that experimental conditions may have varied between groups, the days elapsed since the first blood culture were calculated (as a centred variable) for each analyzed subject. For cancer patients the age at cancer diagnosis and the years elapsed between the end of radiotherapy and chemotherapy and time of MN cultures were also recorded.
Basic descriptive statistics of outcome and continuous variables were computed for all subgroups. The means for between-group demographic and clinical variables were compared using the t-test. To quantify the potential association among continuous and outcome variables, correlation matrices analyses were performed using the Pearson correlation coefficient.
The between-group differences in basal and treatmentinduced MN, NPB and NDI were analyzed using generalized linear models (GLZs). A logarithmic link function was applied to the basal level of MN and NPB to achieve a best fit. The continuous variables that were shown by the correlation analysis to have a possible effect were included in the analyses. In the GLZ analysis of NPB after mutagens treatment, the basal NPB values were considered as a covariable since the treatment-induced NPB values, obtained by subtracting the basal yields from yields obtained after treatment, encompassed negative values which would be difficult to adjust in the GLZ analyses. A backward selection method was used and potential confounding factors that did not reach statistical significance were not considered in the final model. Post hoc comparisons using the sequential Bonferroni correction for multiple comparisons were also carried out.
The figures illustrating the between-group differences in this study show the estimated marginal means, which correspond to the mean adjusted for the other terms in the model.
For all analyses, differences were regarded as statistically significant at P \ 0.05. Statistical computations were performed using the SPSS v.15.0 software (SPSS, Chicago, IL, USA) and the STATISTICA v.8.0 statistical software package (StatSoft, Tulsa, OK, USA).
Results
Demographic, clinical and experimental factors
The mean value of age, days elapsed since first experiment as well as the clinical characteristics of the cancer patient groups are presented in Table 2 . The group of all healthy women was significantly younger than the overall group of cancer patients (P \ 0.001). The peripheral blood cultures for cancer patients were established earlier than the cultures for healthy women and this difference in time, measured as the days elapsed since the first blood culture, was statistically significant (P \ 0.05). The blood cultures of BRCA2 mutation carriers (with and without BC) were set up significantly earlier than the cultures of control group (BC patients and healthy women without familial history of BC) (P \ 0.01). The cultures of familial BC patients negative for BRCA1/2 mutations were established earlier than the cultures of the all other groups and this difference in time is statistically significant (P \ 0.001). The average of the years elapsed since last chemotherapy and radiotherapy sessions in the group of familial BC patients that had no detected mutation in BRCA1/2 is lower, although not statistically significant, than the average of the other BC patient groups.
Basal levels of MN, NPB and NDI Table 3 shows the data (Mean ± SD) for the 3 endpoints evaluated in the untreated lymphocytes from all groups. The analysis of correlation matrices revealed higher basal MN levels when less time had elapsed since the last session of either chemotherapy or radiotherapy in BC patients. The decline in MN yield with time after cancer treatment showed a reasonably good fit to an inverse relationship (r = 0.799, P \ 0.001 and r = 0.725, P \ 0.001 for chemotherapy and radiotherapy, respectively) (Fig. 1a) . The mean lifetime of mature human T lymphocytes varies from 1.5 to 10 years [reviewed in Ref. 14] . Therefore, the data showed in the Fig. 1a are probably reflective of dying off of T lymphocytes with MN that were formed during the time of chemotherapy/radiotherapy. Given that the years elapsed since chemotherapy and radiotherapy were highly correlated, only the variable of chemotherapy was included in the subsequent analyses because it had a higher correlation coefficient with the basal MN level than the radiotherapy variable. The chemotherapy years variable was inverse transformed in order to achieve a linear distribution. This allowed the assignment of a 0 value to the untreated healthy individuals, thereby including them in the analysis.
The results of the GLZ final model indicated that both cancer status (P = 0.014) and the years since last sessions of chemotherapy (P \ 0.001) had a significant effect on the basal level of MN. Thus, the cancer patients showed higher basal MN frequencies than the healthy subjects irrespective of carrier status (20.16 vs. 13.73 as adjusted means for cancer and healthy groups, respectively; P = 0.007) (Fig. 1b) . The significant effect of the time since chemotherapy on basal MN indicates that the frequency of MN is higher when less time had elapsed since cancer therapy.
The GLZ analysis of basal NPB showed significant effects of cancer (P = 0.027) and carrier status (P = 0.018). The NPB in cancer patients were significantly higher than in healthy subjects (1.76 vs. 0.81 as adjusted means for cancer and healthy groups, respectively; P = 0.025) (Fig. 1c) . The carrier status affected the NPB basal level, since the levels of NPB in untreated cultures in both BRCA2 carriers (adjusted mean, 0.80) and familial BC group without detected mutation in BRCA1/2 (0.63) were lower than the levels found in BRCA1 carriers (1.81) and in non-carrier controls (2.22) (Fig. 2) ; nevertheless, the differences between the estimated marginal means, evaluated using the Bonferroni post hoc test, did not attain statistical significance. In terms of NDI levels in the cultures without any treatment, the analysis of the GLZ final models indicated no differences between healthy and cancer groups or between mutation carriers and non-carriers. However, a slight non-significant increase (P = 0.062) in the basal NDI was observed in the group of BRCA2 carriers (adjusted mean, 1.85) compared to that in the BRCA1 (1.79), BRCA1/2 negative (1.75), and non-carrier control (1.77) groups. The final analysis model also showed that both subject age and time elapsed since chemotherapy or radiotherapy significantly affected the proliferation index values. Thus, lower NDI values appeared in older individuals (P = 0.002), and in those with less time elapsed since cancer treatment (P = 0.006).
Effect of the radiation treatment in the G 0 phase Table 4 shows the mean values of MN and NDI induced by radiation and the absolute values of NPB obtained after radiation treatment. The final model of the GLZ analysis did not indicate any effect of cancer or carrier status on MN and NPB after radiation with 2 Gy. Only days elapsed since first blood culture significantly affected both measures. The values of radioinduced MN were higher at the time of final experiments than those at the time of first experiments (P = 0.002), and the frequency of NPB also increased with experimentation time (P \ 0.001).
To evaluate whether in vitro treatment with IR produced alterations in the capacity of cells to divide, we used the NDI value obtained by subtracting the values obtained after (Fig. 3) . The MMC-induced MN of BRCA2 carriers was also higher (135.48) than that of familial cancer patients without detected mutation in BRCA1/2 (111.63), but this difference was not statistically significant ( Fig. 3) . Furthermore, the frequency of MMCinduced MN increased with the continuous variable of days elapsed since the first blood extraction (P \ 0.001). The NPB obtained after MMC treatment was not significantly affected by carrier and cancer status or by any covariable. The evaluation of between-group differences after adjusting the values of MMC-induced NDI for the different confounding factors did not show any significant effect of carrier or disease status on cell proliferation capacity after adding MMC to the cultures. The NDI yielded by MMC was only significantly correlated to the years elapsed since Fig. 3 Adjusted means and 95% confidence limits illustrating the differences of MN levels after MMC treatment between carrier and non-carrier groups. BRCA negative: familial breast cancer patients without detected mutation in BRCA1 or BRCA2. Control non-carriers: healthy women and sporadic BC patients without history of familial cancer treatment for cancer (P = 0.010). This correlation indicated a lower effect of MMC on cell proliferation with less time elapsed since the last cancer treatment. This apparent resistance to MMC in lymphocytes from subjects just treated with chemotherapy or radiotherapy could be explained by the fact that the cellular proliferating potential has been surpassed by the already lower cell proliferation, observed in the non-treated cultures, in subjects after cancer treatments and the high cytostatic effect of MMC (which is stronger than that of the radiation treatment; see NDI values in Tables 4 and 5 ).
Discussion
Chromosomal sensitivity (CRS) to radiation and chemical mutagens, quantified by G 0 MN or G 2 chromosome aberrations assays, has been proposed as a marker for lowpenetrance predisposition to several common cancers including BC [7, [15] [16] [17] . Several independent studies have shown enhanced in vitro sensitivity to the chromosomedamaging effects of ionizing radiation and other mutagens in a significant number of BC patients compared to normal healthy controls [18] [19] [20] [21] [22] . It has been also reported that the enhanced CRS to different mutagens is a heritable trait [19, 21, 23] . The studies that have investigated CRS to mutagens in blood lymphocytes from patients with germline mutations in BRCA1 or BRCA2 have yielded inconsistent results [18, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . While it has been well documented that biallelic inactivation of BRCA1 o BRCA2 (BRCA1 -/-or BRCA2 -/-) genes leads to repair deficiency, and hence to significantly enhanced CRS after treatment with different mutagens, the situation in heterozygous cells (BRCA1 ?/-or BRCA2
?/-) remains elusive.
In our study we assessed the chromosome sensitivity of BRCA1 ?/-or BRCA2 ?/-lymphocytes to IR or MMC treatment measuring MN and NPB with the MN G0 phase assay. Our results showed that, in both cancer and healthy women, heterozygosity for BRCA1/2 mutations did not associated with an increased sensitivity to IR exposure in the G 0 phase. This result contrasts with the findings in lymphocytes heterozygote for BRCA1/2 mutations showing evidence of an enhanced MN radiation induction [7, 18, [32] [33] [34] [35] . However, other studies have not reported a significant increase of MN after radiation in BRCA1/2 mutated lymphocytes [18, 24, 30] . These inconsistent results may be due to small population sizes, heterogeneous reference groups and different techniques used for both irradiation and evaluation of MN [7, 36] .
We found that the frequency of radiation-induced MN as well as the MN induced by MMC increase with the days elapsed since first blood culture. This could not be related to a change in experimental conditions or to reported sources of MN variability such as storage time of the blood samples [37, 38] and differences between scorers [39] . To reduce the inter-test variability, a direct comparison of cases with concurrent controls and/or automated counting by image analysis has been suggested [7, 32] .
The lack of increased radiosensitivity of BRCA1 ?/-or BRCA2
?/-lymphocytes shown in our study may also suggest that the BRCA1/2 proteins do not play a role in the repair mechanisms acting on the radiation-induced DNA damage in the G 0 /G 1 phase such as non-homologous DNA end-joining (NHEJ). NHEJ reseals DNA DSBs efficiently throughout all cell cycle phases but especially in the G 1 phase [40] . Homologous recombination (HR), the other mechanism that the cell employs to repair radiation induced DSBs, acts in the S and G 2 phase when a duplicated copy of DNA is available [41, 42] . Despite some studies have described that BRCA1-deficient cells had significantly reduced NHEJ activity, it is not definitively clear whether BRCA1 or BRCA2 are required for efficient NHEJ of radiation-induced DNA breaks [43, 44] . In contrast, it is well known the role of BRCA1/2 in the functioning of HR pathway [2, 3] .
Given that HR is the most important mechanism for the repair of DSBs induced in the S and G 2 phases [41, 42] , impaired repair of radiation-induced DSBs may be expected at these phases in lymphocytes of BRCA1/2 mutation carriers. When analysing the metaphases after irradiation at S phase Barwell et al. [26] found that the lymphocytes of BRCA1/2 mutation carriers without cancer had increased chromosome breaks compared to age-matched unaffected controls. Blood cells of BRCA1 mutation carriers irradiated with 8 Gy 24 h after stimulation and cultured 6 days following irradiation exhibited a significantly higher level of chromosomal damage than those of non-carrier controls [29] . However, using the G 2 assay, in which metaphases are analysed after irradiation at the G 2 phase of the cell cycle, some authors have described elevated levels of chromosomal aberrations in BRCA1/2 lymphocytes [18, [26] [27] [28] 45] , while other authors have not [24, 25] .
Knowing whether the normal cells of BRCA1/2 mutation carriers exhibit a phenotype of in vitro enhanced radiosensitivity has implications for their cancer screening and treatment using modalities that involve irradiation. Epidemiological studies that have examined whether BRCA1/2 mutation carriers have an increased risk of developing BC related to screening mammography have yield inconsistent results [reviewed in Ref. 46] . Clinical studies of BC women with BRCA1/2 mutations have not demonstrated increased acute or late toxicity after radiotherapy [47] . However, Broeks et al. [48] suggested that pathogenic alleles in BRCA1/2, CHEK2 or ATM genes increase the risk of radiation-induced contralateral BC after radiotherapy for a first BC. It is clear that more and larger studies are warranted to determine the in vitro and in vivo radiosensitivity phenotype of BRCA1/2 normal cells.
In contrast to the lack of increased in vitro sensitivity to radiation observed in our study, BRCA2 mutations confer enhanced MMC susceptibility on blood lymphocytes of both cancer and healthy women (Fig. 3) . Hence, the heterozygosity status for BRCA2 mutations probably affects the DNA repair capacity for MMC-induced damage in the G 1 /S phase of lymphocytes. To our knowledge, there are only 2 published studies on the effects of MMC on normal cells heterozygous for BRCA1/2. Shorrocks et al. [49] found no differences in MN response between BRCA1
?/-and ?/? fibroblasts. Arnold et al. [6] measured by the Comet assay the repair of MMC-induced crosslinks and observed no clear differences in repair capacity between BRCA2
?/-and BRCA2 ?/? lymphoblastoid cell lines. Although the repair of MMC-induced DNA damage in mammals has not been fully delineated, MMC induces several types of DNA damage that are repaired by multiple repair mechanisms such as nucleotide excision repair, HR and trans-lesion bypass repair [reviewed in Ref. 50] . Under the experimental conditions used in our study, our results indicate a relevant role for BRCA2 in the repair of MMCinduced lesions in the G 1 /S phase but not for BRCA1. In this regard Venkitaraman [5] suggested that defects in DSBs repair in BRCA1/2 mutated cells arise from distinct roles for BRCA1 or BRCA2 in HR. The major role of BRCA2 protein in DSB repair is the regulation of HR, acting as a mediator of interactions with RAD51 protein, while the functions of BRCA1 in DNA repair are not restricted to HR, performing varied functions in the cellular response to DNA breakage or replication arrest.
Our results with MMC may concur with those of some studies reporting high sensitivity to in vitro and in vivo MMC treatment of a pancreatic cancer cell line defective in BRCA2 [51] or the response to a third-line MMC-based chemotherapy of a metastatic pancreatic adenocarcinoma in a BRCA2 carrier patient [52] . Moreover, treatment of blood lymphocytes with MMC may be used to distinguish BRCA2 mutation carriers and identify new BRCA2 interacting genes.
The endpoint of NPBs is an indicator of DNA misrepair and/or telomere end-fusions [8] . With regard to this endpoint, the only significant finding we observed in our study was that BRCA2 carriers, irrespective of their cancer status, and the familial BC patients without detected mutation in BRCA1/2 had lower basal levels of NPB compared with those of BRCA1 and non-carrier control groups (Fig. 2) . A similar trend was also observed by Beetstra et al. [53] , who found that, in folate deficient medium cultures, the lymphocytes of BRCA2 mutation carriers had a significantly lower frequency of NPB compared with controls. These authors suggested that the lower number of NPB may be due to an extended delay in cell division of BRCA2 carriers. An extended cell division would allow more time for the bridges to break during anaphase prior to cell harvesting. Beetstra et al. [53] based their hypothesis on data obtained by Daniels et al. [54] , who reported that the period taken for cells to progress from anaphase onset to completion of cell division is significantly extended in cells with targeted gene disruption of BRCA2 or reduced transcription of BRCA2 by RNA interference when compared with controls. Likewise, Jonsdottir et al. [55] have demonstrated that BRCA2 mutation carrier fibroblasts had delayed cytokinesis, being the mean cell division time 6 min longer compared with BRCA2 wild-type cells. However, in contrast to results from these two studies, Lekomtsev et al. [56] have recently indicated that BRCA2 does not regulate cytokinesis in human cells. Thus, further research is required to verify a role of BRCA2 in the regulation of cell division. Interestingly, in the familial BC patients without detected mutation in BRCA1/2 a decrease in the basal NPB formation was also detected. It is tempting to speculate that BRCA2 and other genes related to cell division might be associated with cancer susceptibility in familial BC patients negative for BRCA1/2 mutations.
It should be mentioned that the group of familial BC patients who tested negative for BRCA1/2 mutations did not present a different CRS to either radiation or MMC treatment compared with control non-carriers. These data do not support the findings of the studies carried out by Baeyens et al. [18, 24] . They showed that the lymphocytes of non-BRCA1/2 familial BC patients had a higher CRS to radiation, measured by G 0 MN and G 2 assays, than the control group. Further research will be needed to more precisely determine the CRS in the group of familial BC with no BRCA1/2 mutations.
The NDI provides a measure of the proliferative status of the viable lymphocytes, indicating both the lymphocyte mitogenic response and the cytostatic effects of agents examined in the assay [8] . We did not find any significant difference in either basal or mutagen-induced levels of this proliferation index between BRCA1/2 carriers and noncarrier groups; this would indicate that the lymphocytes from heterozygous BRCA1/2 mutation carriers have no important defects in the mitogenic response or cellular growth in culture after mutagenic treatments. However, it is interesting to note that, although differences were not statistically significant, the BRCA2 carriers showed higher basal levels of NDI values than the other groups analysed. A similar finding has been reported by Beetstra et al. [53] , who detected that the NDI of BRCA2 mutation carriers in lymphocytes cultured with folate deficiency tended to be higher than in controls. Thus, the BRCA2 carriers may have a defect in cytokinesis that entails an increased sensitivity to the cytokinesis-blocking action of cytochalasin-B [53] . This may be attributed to an extended time for these cells to progress from anaphase onset to completed cell division that allows the accumulation of binucleated cells in culture [54, 55] .
In conclusion, the BRCA1 or BRCA2 heterozygote status in peripheral blood lymphocytes is not related to an increased radiosensitivity. But the monoallelic BRCA2 mutations are associated with a higher level of chromosomal damage induced by MMC, probably due to an impaired DNA repair capacity. This finding suggests that the MMC-induced MN analysis may be used in the identification of individuals with a deficiency in BRCA2 or genes related to BRCA2. Given that MMC can be used as an anti-cancer drug, these data may be relevant for the management and follow-up of BRCA2 mutation carriers.
